Title: Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.
Journal: Drugs 20170701
Title: Metabolism and Disposition of Hepatitis C Polymerase Inhibitor Dasabuvir in Humans.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20160801
Title: Dasabuvir (ABT333) for the treatment of chronic HCV genotype I: a new face of cure, an expert review.
Journal: Expert review of anti-infective therapy 20160101
Title: New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir.
Journal: Expert review of clinical pharmacology 20160101
Title: Interferon-free therapy for hepatitis C: The hurdles amid a golden era.
Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20150901
Title: Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection.
Journal: The Annals of pharmacotherapy 20150501
Title: Dasabuvir : a new direct antiviral agent for the treatment of hepatitis C.
Journal: Expert opinion on pharmacotherapy 20150301
Title: An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver.
Journal: Canadian journal of gastroenterology & hepatology 20150101
Title: Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A.
Journal: Journal of medicinal chemistry 20140313
Title: Dasabuvir: A Non-Nucleoside Inhibitor of NS5B for the Treatment of Hepatitis C Virus Infection.
Journal: Reviews on recent clinical trials 20140101
Title: Kati W, et al. In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother. 2015 Mar;59(3):1505-11.
